Last reviewed · How we verify
NCT06911645
Diagnostic Reasoning With Customized GPT-4 Model
NA trial testing Immediate access to customized version of GPT-4 in Pathologic Processes in 70 participants. Completed in 24 January 2025.
24 January 2025
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 70 |
| Start date | 16 December 2024 |
| Primary completion | 24 January 2025 |
| Estimated completion | 24 January 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Immediate access to customized version of GPT-4
- Access to customized version of GPT-4 following use of conventional resources
Conditions studied
- Pathologic Processes — all drugs for Pathologic Processes →
- Disease — all drugs for Disease →
Sponsor
Stanford University
Who can join
Eligibility, any sex, with Pathologic Processes or Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the impact of immediate access to a customized version of GPT-4, a large language model, on performance in case-based diagnostic reasoning tasks. Specifically, it will compare this approach to a two-step process where participants first use traditional diagnostic decision support tools to support their diagnostic reasoning before gaining access to the customized GPT-4 model.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
From tool to teammate in a randomized controlled trial of clinician-AI collaborative workflows for diagnosis.
Everett SS, Bunning BJ, Jain P, Lopez I, et al · · 2026 · PMID 41851268 · DOI 10.1038/s41746-026-02545-1
Verify or expand the search:
- PubMed search for NCT06911645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pathologic Processes
Currently open trials in the same condition.
- NCT06674980 — Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DF · NA · recruiting
- NCT06271538 — Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome · Phase 4 · recruiting
- NCT06374225 — Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention · NA · active not recruiting
- NCT05452356 — Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care) · recruiting
- NCT05969275 — Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock · Phase 2 · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06911645 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06911645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing